Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-chloro-5-[2-chloro-5-(1H-indazol-3-ylmethoxy)phenoxy]benzonitrile is an experimental small molecule compound belonging to the class of diphenylethers, characterized by two benzene rings connected via an ether linkage. It has a molecular formula of C21H13Cl2N3O2 and a molecular weight of approximately 410.25 g/mol. The compound is not approved for clinical use in any country and has no reported indications or clinical trials beyond preclinical/experimental status. Its mechanism of action, biological targets, and therapeutic potential are not described in publicly available sources[1][6]. There is no evidence it has reached any stage of human clinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-chloro-5-[2-chloro-5-(1H-indazol-3-ylmethoxy)phenoxy]benzonitrile.